Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q3 2024 · 10-Q
Revenue$4.21B$4.21B+19.3% vs Q3 2023 Net Income$468.00M$468.00M−7.1% vs Q3 2023 EPS Diluted$0.32$0.32−5.9% vs Q3 2023 Gross Profit$2,897,000,000+19.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,002,000,000+43.6% Free Cash Flowderived$823,000,000+62.0% Margins · derivedGross margin68.8%+0.0 pt vs Q3 2023
Operating margin17.4%−2.2 pt vs Q3 2023
Net margin11.1%−3.2 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 1, 2024 · 32 d after period end